

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM862799

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	MERGER		
EFFECTIVE DATE:	03/31/2020		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Horizon Pharma Rheumatology LLC		03/31/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Horizon Therapeutics USA, Inc.		
Street Address:	1 Horizon Way		
City:	Deerfield		
State/Country:	ILLINOIS		
Postal Code:	60015		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1508914	MIGERGOT	
CORRESPONDENCE DATA			
Fax Number:	2122919868		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(212) 558-4229		
Email:	demarcor@sullcrom.com, nguyenb@sullcrom.com, maken@sullcrom.com		
Correspondent Name:	Raffaele A. DeMarco		
Address Line 1:	125 Broad Street		
Address Line 2:	Sullivan & Cromwell LLP		
Address Line 4:	New York, NEW YORK 10004		
NAME OF SUBMITTER:	Raffaele DeMarco		
SIGNATURE:	/Raffaele A. DeMarco/		
DATE SIGNED:	12/21/2023		
Total Attachments: 2			
source=9. Horizon Pharma Rheumatology LLC- DE -Copy 4875-5896-3602 v.1#page1.tif			
source=9. Horizon Pharma Rheumatology LLC- DE -Copy 4875-5896-3602 v.1#page2.tif			

OP \$40.00 1508914

**CERTIFICATE OF MERGER
OF
HORIZON PHARMA RHEUMATOLOGY LLC
WITH AND INTO
HORIZON THERAPEUTICS USA, INC.**

MARCH 31, 2020

Pursuant to Section 264(c) of the Delaware General Corporation Law and Section 18-209 of the Delaware Limited Liability Company Act, Horizon Therapeutics USA, Inc., a Delaware corporation, does hereby certify the following information in connection with the merger of Horizon Pharma Rheumatology LLC, a Delaware limited liability company, with and into Horizon Therapeutics USA, Inc. (the "Merger"):

FIRST: The name and state of incorporation or formation, as applicable, of each of the constituent entities in the Merger are as follows (the "Constituent Entities"):

<u>Name</u>	<u>State of Incorporation or Formation</u>
Horizon Therapeutics USA, Inc.	Delaware
Horizon Pharma Rheumatology LLC	Delaware

SECOND: The Agreement and Plan of Merger by and between the Constituent Entities has been approved, adopted, certified, executed and acknowledged by each Constituent Entity in accordance with Section 264(c) of the Delaware General Corporation Law.

THIRD: The name of the surviving entity in the Merger (the "Surviving Entity") is "Horizon Therapeutics USA, Inc."

FOURTH: The certificate of incorporation of Horizon Therapeutics USA, Inc. as in effect immediately prior to the Merger shall be the certificate of incorporation of the Surviving Entity until thereafter amended as provided therein or by applicable law.

FIFTH: The Agreement and Plan of Merger is on file at the principal place of business of the Surviving Entity, the address of which is 150 South Saunders Road, Lake Forest, Illinois, 60045.

SIXTH: A copy of the Agreement and Plan of Merger will be furnished by the Surviving Entity on request, without cost, to any stockholder of any constituent corporation or member of any constituent limited liability company.

SEVENTH: The Merger shall become effective immediately upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

* * *

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Merger on the date first written above.

HORIZON THERAPEUTICS USA, INC.

By: 
Name: Paul Hoelscher
Title: EVP, Chief Financial Officer